InnovAge (NASDAQ:INNV) Stock Rating Upgraded by Zacks Research

InnovAge logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zacks Research upgraded InnovAge from “hold” to “strong buy.” Other analyst views vary, leaving the stock with a MarketBeat consensus rating of “Moderate Buy” and a $10.50 average price target.
  • InnovAge reported quarterly EPS of $0.14, beating the $0.09 consensus estimate, and revenue of $264.76 million, above forecasts of $257.23 million.
  • Company insiders sold a total of 13.0 million shares worth about $120.5 million over the past 90 days.
  • MarketBeat previews the top five stocks to own by December 1st.

InnovAge (NASDAQ:INNV - Get Free Report) was upgraded by stock analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a report released on Monday, Zacks reports.

A number of other research analysts have also recently issued reports on the stock. Wall Street Zen raised shares of InnovAge from a "buy" rating to a "strong-buy" rating in a report on Saturday, November 7th. Weiss Ratings upgraded InnovAge from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Wednesday, November 4th. Finally, KeyCorp lifted their price target on InnovAge from $13.00 to $14.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, InnovAge presently has an average rating of "Moderate Buy" and a consensus price target of $10.50.

Read Our Latest Report on InnovAge

InnovAge Price Performance

Shares of INNV stock opened at $9.42 on Monday. InnovAge has a fifty-two week low of $4.70 and a fifty-two week high of $12.64. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.16 and a current ratio of 1.16. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of 159.67 and a beta of 0.16. The stock's 50-day simple moving average is $9.46 and its 200-day simple moving average is $9.25.

InnovAge (NASDAQ:INNV - Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. The firm had revenue of $264.76 million during the quarter, compared to analyst estimates of $257.23 million. InnovAge had a net margin of 0.88% and a return on equity of 3.63%. As a group, equities analysts forecast that InnovAge will post 0.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Carson Anderson & Stow Welsh sold 1,500,000 shares of the business's stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $9.25, for a total transaction of $13,875,000.00. Following the completion of the transaction, the insider directly owned 101,076,555 shares in the company, valued at $934,958,133.75. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Nicole Damato sold 23,814 shares of the company's stock in a transaction on Friday, September 25th. The shares were sold at an average price of $8.70, for a total transaction of $207,181.80. Following the completion of the sale, the insider directly owned 304,897 shares in the company, valued at approximately $2,652,603.90. The trade was a 7.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,027,216 shares of company stock valued at $120,489,535 over the last 90 days. Insiders own 1.10% of the company's stock.

Hedge Funds Weigh In On InnovAge

Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in InnovAge during the second quarter valued at approximately $17,652,000. Algert Global LLC boosted its position in InnovAge by 844.1% in the 2nd quarter. Algert Global LLC now owns 630,520 shares of the company's stock worth $7,472,000 after purchasing an additional 563,735 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in InnovAge by 207.1% in the 3rd quarter. Goldman Sachs Group Inc. now owns 668,219 shares of the company's stock worth $5,880,000 after purchasing an additional 450,610 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in shares of InnovAge during the 1st quarter worth approximately $3,349,000. Finally, Marshall Wace LLP acquired a new stake in shares of InnovAge during the 3rd quarter worth approximately $3,589,000. Institutional investors and hedge funds own 12.26% of the company's stock.

About InnovAge

(Get Free Report)

InnovAge, Inc. provides integrated healthcare and social services to older adults through the Program of All-Inclusive Care for the Elderly (PACE). The program serves people who qualify for nursing-home-level care but can continue living in their communities with coordinated support. InnovAge's services include primary and specialty care coordination, nursing, rehabilitation, social services, prescription medications, transportation, in-home assistance and adult day health services. Care is coordinated by interdisciplinary teams and delivered through a combination of community-based centers and support at home.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in InnovAge Right Now?

Before you consider InnovAge, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InnovAge wasn't on the list.

While InnovAge currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines